Wave Life Sciences Ltd. – NASDAQ:WVE
Wave Life Sciences Ltd. stock price today
$9.52
-3.38
-26.2%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in 1 minute
Wave Life Sciences Ltd. stock price monthly change
+129.54%
month
Wave Life Sciences Ltd. stock price quarterly change
+129.54%
quarter
Wave Life Sciences Ltd. stock price yearly change
+153.44%
year
Wave Life Sciences Ltd. key metrics
Market Cap | 2.06B |
Enterprise value | 318.95M |
P/E | -2.29 |
EV/Sales | 55.23 |
EV/EBITDA | -1.16 |
Price/Sales | 64.05 |
Price/Book | -8.20 |
PEG ratio | -0.17 |
EPS | -0.52 |
Revenue | 112.91M |
EBITDA | -70.06M |
Income | -61.66M |
Revenue Q/Q | -3.02% |
Revenue Y/Y | 661.49% |
Profit margin | -4172.72% |
Oper. margin | -4208.14% |
Gross margin | 6.49% |
EBIT margin | -4208.14% |
EBITDA margin | -62.05% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeWave Life Sciences Ltd. stock price history
Wave Life Sciences Ltd. stock forecast
Wave Life Sciences Ltd. financial statements
Average Price Target
$20.75
Potential upside: 117.96%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 22.10M | -21.10M | -95.47% |
|---|---|---|---|
| Sep 2023 | 49.21M | 7.25M | 14.74% |
| Dec 2023 | 29.05M | -16.25M | -55.95% |
| Mar 2024 | 12.53M | -31.55M | -251.7% |
| 2024-03-06 | -0.19 | -0.15 |
|---|---|---|
| 2024-05-09 | -0.18 | -0.24 |
| Jun 2023 | 229985000 | 281.70M | 122.49% |
|---|---|---|---|
| Sep 2023 | 199918000 | 240.40M | 120.25% |
| Dec 2023 | 274949000 | 227.44M | 82.72% |
| Mar 2024 | 235270000 | 202.00M | 85.86% |
| Jun 2023 | -37.25M | -72K | 1.84M |
|---|---|---|---|
| Sep 2023 | -34.45M | -198K | 1.67M |
| Dec 2023 | -33.05M | -354.39K | 93.47M |
| Mar 2024 | -33.43M | -417K | 14.51M |
Wave Life Sciences Ltd. alternative data
| Aug 2023 | 250 |
|---|---|
| Sep 2023 | 250 |
| Oct 2023 | 250 |
| Nov 2023 | 250 |
| Dec 2023 | 250 |
| Jan 2024 | 250 |
| Feb 2024 | 250 |
| Mar 2024 | 266 |
| Apr 2024 | 266 |
| May 2024 | 266 |
| Jun 2024 | 266 |
| Jul 2024 | 266 |
Wave Life Sciences Ltd. other data
19.54%
-53.02%
of WVE is owned by hedge funds
35
-39
15.40M
-52.72M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 2000000 | 0 |
| Apr 2024 | 0 | 15630 |
| Aug 2024 | 0 | 48366 |
| Sep 2024 | 2791930 | 17146 |
| Oct 2024 | 0 | 299310 |
| Nov 2024 | 0 | 137234 |
| Patent |
|---|
Grant Filling date: 13 Mar 2017 Issue date: 9 Aug 2022 |
Application Filling date: 14 Jul 2021 Issue date: 23 Jun 2022 |
Application Filling date: 6 Dec 2019 Issue date: 16 Jun 2022 |
Application Filling date: 7 May 2020 Issue date: 26 May 2022 |
Application Filling date: 8 May 2020 Issue date: 12 May 2022 |
Application Filling date: 2 Sep 2021 Issue date: 28 Apr 2022 |
Application Filling date: 30 Jan 2020 Issue date: 31 Mar 2022 |
Grant Utility: Asymmetric auxiliary group Filling date: 19 May 2020 Issue date: 5 Oct 2021 |
Application Filling date: 10 May 2019 Issue date: 19 Aug 2021 |
Application Filling date: 12 Oct 2018 Issue date: 29 Jul 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 6 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Paul B. Bolno M.B.A., M.D., MBA (1974) Pres, Chief Executive Officer & Director | $961,470 |
| Dr. Michael A. Panzara M.D., M.P.H., MPH (1967) Chief Medical Officer and Head of Therapeutics Discovery & Devel. | $655,000 |
| Dr. Chandra Vargeese Ph.D. (1961) Chief Technology Officer | $619,200 |
Wave Life Sciences Is A Buy On Pipeline Prospects
Biogen: LAQEMBI's $10 Billion Potential
Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash
Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)
Wave Life Sciences: Huntington's Hypotheses, GSK Collaboration Catalysts To Move The Needle
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
Week 52 MDA Breakout Stocks - December 2022: Short-Term Picks To Give You An Edge
MDA Breakout Stocks Week 45 - November 2022: Short-Term Picks To Give You An Edge
MDA Breakout Stocks Week 44 - November 2022: Short-Term Picks To Give You An Edge
-
What's the price of Wave Life Sciences Ltd. stock today?
One share of Wave Life Sciences Ltd. stock can currently be purchased for approximately $9.52.
-
When is Wave Life Sciences Ltd.'s next earnings date?
Unfortunately, Wave Life Sciences Ltd.'s (WVE) next earnings date is currently unknown.
-
Does Wave Life Sciences Ltd. pay dividends?
No, Wave Life Sciences Ltd. does not pay dividends.
-
How much money does Wave Life Sciences Ltd. make?
Wave Life Sciences Ltd. has a market capitalization of 2.06B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 3005.1% to 113.31M US dollars. Wave Life Sciences Ltd. made a loss 57.51M US dollars in net income (profit) last year or -$0.24 on an earnings per share basis.
-
What is Wave Life Sciences Ltd.'s stock symbol?
Wave Life Sciences Ltd. is traded on the NASDAQ under the ticker symbol "WVE".
-
What is Wave Life Sciences Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Wave Life Sciences Ltd.?
Shares of Wave Life Sciences Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Wave Life Sciences Ltd.'s key executives?
Wave Life Sciences Ltd.'s management team includes the following people:
- Dr. Paul B. Bolno M.B.A., M.D., MBA Pres, Chief Executive Officer & Director(age: 51, pay: $961,470)
- Dr. Michael A. Panzara M.D., M.P.H., MPH Chief Medical Officer and Head of Therapeutics Discovery & Devel.(age: 58, pay: $655,000)
- Dr. Chandra Vargeese Ph.D. Chief Technology Officer(age: 64, pay: $619,200)
-
How many employees does Wave Life Sciences Ltd. have?
As Jul 2024, Wave Life Sciences Ltd. employs 266 workers.
-
When Wave Life Sciences Ltd. went public?
Wave Life Sciences Ltd. is publicly traded company for more then 9 years since IPO on 11 Nov 2015.
-
What is Wave Life Sciences Ltd.'s official website?
The official website for Wave Life Sciences Ltd. is wavelifesciences.com.
-
How can i contact Wave Life Sciences Ltd.?
Wave Life Sciences Ltd. can be reached via phone at +65 6236 3388.
-
What is Wave Life Sciences Ltd. stock forecast & price target?
Based on 7 Wall Street analysts` predicted price targets for Wave Life Sciences Ltd. in the last 12 months, the avarage price target is $20.75. The average price target represents a 117.96% change from the last price of $9.52.
Wave Life Sciences Ltd. company profile:
Wave Life Sciences Ltd.
wavelifesciences.comExchange:
NASDAQ
Full time employees:
266
Industry:
Biotechnology
Sector:
Healthcare
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Marina One East Tower
Singapore, 018936
Singapore, 018936
CIK: 0001631574
ISIN: SG9999014716
CUSIP: Y95308105
